Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023
August 08, 2023 at 04:09 pm EDT
Share
Veracyte, Inc. revises revenue guidance for the full year 2023. The company is raising full-year 2023 total revenue guidance to $342 million to $350 million, representing year-over- year growth of 15% to 18%, and an improvement compared to prior guidance of $330 million to $340 million.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
VERACYTE, INC. 
